Dr. John Cush RheumNow
7 years 2 months ago
Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY
While often seen as demanding, millennial patients have grown accustomed to having direct access to everything and everyone. They tend to be more involved in the clinical evaluation in the office, more concerned about the social aspects of the disease, and are more frustrated with the varying shades of gray in diagnoses and delayed treatment efficacy. What does this mean for you and your practice?
Dr. John Cush RheumNow
7 years 2 months ago
Testosterone replacement therapy Increases the risk of CV events (MI/CVA/TIA). Study of 15,401 men, >45 yrs old, w/ low testosterone & no evidence of hypogonadotropic or testicular dz (1995-2017). HR 1.21; CI 1.0-1.46), highest in the 1st 2yrs https://t.co/nNXyFIo1EH
Dr. John Cush RheumNow
7 years 2 months ago
Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a negative opinion on Application for romosozumab (Evenity) for the treatment of severe osteoporosis (by Amgen & UCB); an appeal is planned https://t.co/EVjxuBQdF0
Dr. John Cush RheumNow
7 years 2 months ago
Im starting a War on RA. I need you go get mad and do your part. Read 1st of 4 part series https://t.co/sR5Z3lq8CU or watch it here https://t.co/s7CVW2dNUT
Dr. John Cush RheumNow
7 years 2 months ago
The FDA Arthritis Advisory Committee voted 10-7 in favor of approving the to consider the antifibrotic drug, nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/UNlpQNJAim
Dr. John Cush RheumNow
7 years 2 months ago
The RheumNow Podcast is up! News, Announcements of generics/biosimilars, approvals and FDA hearings. Watch the video here>> https://t.co/3tW7uRivgQ or listen to the podcast on iTunes>> https://t.co/q2bscJkIhs
NEJM NEJM
7 years 2 months ago
Image challenge: A 48-year-old man presented to the dermatology clinic with a 6-month history of painful hand ulcerations and shortness of breath. He has no muscle weakness or arthritis. What is the diagnosis? https://t.co/kQrNuVExlQ https://t.co/n3435OCPLA
Dr. John Cush RheumNow
7 years 2 months ago
The FDA Arthritis Advisory Committee has voted 10-7 in favor of approving the to consider the antifibrotic drug, nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/UNlpQNJAim
Peter Nash drpnash
7 years 2 months ago
Effect of Filgotinib in Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drugs - JAMA July 23/30 - Filgo (Jak1 inhib) efficacy in Bdmard-IR - selling point for Filgo = less Zoster, 300 pts for 6 mths 1.4% zoster in this study so watch this space
Angus Worthing MD AngusWorthing
7 years 2 months ago
A lot happening on reforms to curb high drug prices! Yesterday, @ChuckGrassley & @RonWyden's bill cleared Senate Finance Committee & I think there are positives and negatives. You can see @ACRheum letters to leaders on this & other issues @ this link:
https://t.co/AA8JrONPsa https://t.co/KnGHAXmRFE
The Journal of Rheumatology jrheum
7 years 2 months ago
The Assessment of Disease Activity in Psoriatic Arthritis: MDA, VLDA, DAPSA, or Something Else? https://t.co/jmyA5KABzM #diseaseactivity #remission #psoriaticarthritis
Dr. John Cush RheumNow
7 years 2 months ago
Samsung Bioepsis has announced an update to the EU product label for its adalimumab biosimilar IMRALDI - adding the drug can be stored in non-refrigerated conditions (up to 25˚C or 77F) for up to 28 days https://t.co/nGgxZDBQyC
Dr. John Cush RheumNow
7 years 2 months ago
FDA puts a New Boxed Warning on #tofacitinib for Blood Clots and Death with Higher Doses (10 mg bid). https://t.co/Bzgst3ooo0
Dr. Jack Cush reviews the news, journal reports, and FDA releases and deliberations covered this past week on RheumNow.com
